Victoza for weight loss: what GLP-1 TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtags, @weightlosswithgil is documenting a personal weight loss journey using Victoza (liraglutide), a GLP-1 receptor agonist approved by the FDA for type 2 diabetes management at doses up to 1.8 mg daily, and for chronic weight management under the brand name Saxenda at doses up to 3.0 mg daily. The hashtag "cheatingthesystem" is a red flag worth paying attention to. It signals the video may be framing liraglutide as a shortcut or hack rather than a medication with a specific clinical profile and risk profile. The creator is likely showing injection technique, early weight loss results, and possibly appetite suppression experiences. Day 19 content typically focuses on initial side effects or early scale wins, neither of which tells you much about long-term outcomes. This is anecdote dressed as evidence, and the audience of nearly 20,000 viewers deserves more context than a hashtag journey provides.

What does the science actually show?

Liraglutide has a legitimate evidence base, but the numbers are more modest than GLP-1 TikTok would have you believe. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed liraglutide 3.0 mg produced mean weight loss of 8.4 kg over 56 weeks compared to 2.8 kg with placebo. That is meaningful, but it is not the dramatic 20-plus percent body weight reduction people associate with semaglutide. For context, the STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg achieved 14.9% mean body weight reduction. Liraglutide also requires daily injections versus once-weekly semaglutide, which affects real-world adherence. , the SCALE trial also recorded that 26.1% of liraglutide users discontinued due to adverse events, primarily gastrointestinal. Nineteen days of injections is a snapshot at the exact point when side effects are typically peaking and before meaningful fat loss is even measurable.

Where does the social media noise diverge from clinical reality?

The GLP-1 content ecosystem on TikTok has a structural problem: it rewards early, dramatic posts and punishes nuanced long-term updates. A creator on day 19 is essentially reporting from the nausea phase, not the outcomes phase. The hashtag "gpl1community" (note the misspelling, which is consistent across GLP-1 TikTok) functions as a peer-validation network that normalizes off-label use, dose escalation based on anecdote, and sourcing medications outside regulated channels. Victoza is specifically approved for type 2 diabetes, not primary obesity treatment. Using it off-label for weight loss in someone without a diabetes diagnosis is a clinical decision that requires physician oversight, not a TikTok comment section. There is also a meaningful difference between Victoza (liraglutide 1.8 mg max for diabetes) and Saxenda (liraglutide 3.0 mg for weight management). These are not interchangeable, and conflating them in a general hashtag feed creates real confusion about appropriate dosing and indication.

What should you actually know?

If you are considering liraglutide for weight management, a few things are worth knowing before you take injection advice from a 19-day TikTok diary. First, liraglutide carries an FDA boxed warning for thyroid C-cell tumors based on animal studies. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Second, insurance coverage for Saxenda remains inconsistent, and Victoza prescribed off-label for weight loss is frequently not covered, making cost a real access issue. Third, weight regain after stopping GLP-1 therapy is well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed participants regained two-thirds of lost weight within one year of stopping semaglutide. Liraglutide data shows similar patterns. The "cheatingthesystem" framing concerns us most. This is a medication with a mechanism, a risk profile, and a discontinuation problem. It is not a cheat code.